Campoli M - Search Results

1

Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies.

Wang X, Campoli M, Ko E, Luo W, Ferrone S. Wang X, et al. Among authors: campoli m. J Immunol Methods. 2004 Nov;294(1-2):23-35. doi: 10.1016/j.jim.2004.08.005. J Immunol Methods. 2004. PMID: 15604013

2

A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections.

Wang X, Campoli M, Cho HS, Ogino T, Bandoh N, Shen J, Hur SY, Kageshita T, Ferrone S. Wang X, et al. Among authors: campoli m. J Immunol Methods. 2005 Apr;299(1-2):139-51. doi: 10.1016/j.jim.2005.02.006. Epub 2005 Apr 1. J Immunol Methods. 2005. PMID: 15896802

3

HLA class I antigen loss, tumor immune escape and immune selection.

Campoli M, Chang CC, Ferrone S. Campoli M, et al. Vaccine. 2002 Dec 19;20 Suppl 4:A40-5. doi: 10.1016/s0264-410x(02)00386-9. Vaccine. 2002. PMID: 12477427 Review.

4

HLA class I defects in malignant lesions: what have we learned?

Chang CC, Campoli M, Ferrone S. Chang CC, et al. Among authors: campoli m. Keio J Med. 2003 Dec;52(4):220-9. doi: 10.2302/kjm.52.220. Keio J Med. 2003. PMID: 14748474 Free article. Review.

5

T-cell-based immunotherapy of melanoma: what have we learned and how can we improve?

Campoli M, Ferrone S. Campoli M, et al. Expert Rev Vaccines. 2004 Apr;3(2):171-87. doi: 10.1586/14760584.3.2.171. Expert Rev Vaccines. 2004. PMID: 15056043 Free article. Review.

6

HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis?

Chang CC, Campoli M, Ferrone S. Chang CC, et al. Among authors: campoli m. Curr Opin Immunol. 2004 Oct;16(5):644-50. doi: 10.1016/j.coi.2004.07.015. Curr Opin Immunol. 2004. PMID: 15342012 Review.

7

Immunotherapy of melanoma targeting human high molecular weight melanoma-associated antigen: potential role of nonimmunological mechanisms.

Chang CC, Campoli M, Luo W, Zhao W, Zaenker KS, Ferrone S. Chang CC, et al. Among authors: campoli m. Ann N Y Acad Sci. 2004 Dec;1028:340-50. doi: 10.1196/annals.1322.040. Ann N Y Acad Sci. 2004. PMID: 15650259 Review.

8

Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance.

Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S. Campoli MR, et al. Crit Rev Immunol. 2004;24(4):267-96. doi: 10.1615/critrevimmunol.v24.i4.40. Crit Rev Immunol. 2004. PMID: 15588226 Review.

9

Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy.

Chang CC, Campoli M, Restifo NP, Wang X, Ferrone S. Chang CC, et al. Among authors: campoli m. J Immunol. 2005 Feb 1;174(3):1462-71. doi: 10.4049/jimmunol.174.3.1462. J Immunol. 2005. PMID: 15661905 Free PMC article.

10

HLA antigen changes in malignant tumors of mammary epithelial origin: molecular mechanisms and clinical implications.

Campoli M, Chang CC, Oldford SA, Edgecombe AD, Drover S, Ferrone S. Campoli M, et al. Breast Dis. 2004;20:105-25. doi: 10.3233/bd-2004-20112. Breast Dis. 2004. PMID: 15687712 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Search Page

Filters